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OBJECTIVES We sought to evaluate the safety and efficacy of carotid artery stenting (CAS) in high risk
patients.
BACKGROUND Carotid endarterectomy (CE) has been shown to be more effective than medical therapy, but
it has limitations. Carotid artery stenting may be a reasonable alternative, particularly in
high-risk patients.
METHODS We prospectively evaluated the safety and efficacy of CAS in 170 consecutive patients who
underwent the procedure in 192 carotid arteries. Of the patients enrolled, 129 (76%) would
have been excluded from the major trials of CE and 54 (32%) were referred by vascular
surgeons. This series represents a very high-risk group that included patients with unstable
angina, previous ipsilateral CE, contralateral carotid artery occlusion and other severe
comorbid illnesses. Only 25 (24%) of 104 symptomatic patients would have met the North
American Symptomatic Carotid Endarterectomy Trial (NASCET) entry criteria. The
patients’ mean age was 73 6 8 years (95 confidence interval [CI] 57 to 89), and 42 patients
(25%) were $80 years old. Patients had an independent neurologic examination before and
after the procedure.
RESULTS The procedural success rate was 99%, including 73 patients who had a coronary intervention.
Mean carotid artery stenosis was 78 6 10% before (95 CI 58 to 98) and 2 6 3% after the
procedure (95 CI 24 to 8). During the initial hospital period and 30 days after CAS, there
was one major and two category 2 minor strokes, as well as two category 1 minor strokes (total
30-day stroke rate was 2.9% for treated patients or 2.6% for treated arteries). There were no
myocardial infarctions or deaths during or within 30 days of CAS. None of the NASCET-
eligible patients had a stroke. At a mean follow-up of 19 6 11 months, three patients (2%)
had asymptomatic restenosis. No other major strokes or neurologic deaths occurred.
CONCLUSIONS Carotid artery stenting is feasible, can be performed even in high-risk patients and is
associated with a low restenosis rate. (J Am Coll Cardiol 2000;35:1721–8) © 2000 by the
American College of Cardiology
Cerebrovascular accidents (CVAs) occur each year in
500,000 Americans and result in 150,000 deaths and in
substantial morbidity (1). Although antiplatelet agents have
a continuing role in reducing CVA risk, randomized,
controlled trials have shown that a reduction in carotid
artery stenosis by carotid endarterectomy (CE) is superior to
that of medical therapy alone (2–4).
Carotid endarterectomy, however, has certain limitations.
In the North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET), 5.8% of patients had perioperative
stroke or death (2). In the Asymptomatic Carotid Athero-
sclerosis Study (ACAS), the perioperative stroke rate was
2.8% (4). In higher-risk patients, particularly those with
severe CAD, perioperative morbidity and mortality have
been reported in up to 18% of patients (1,5–14). Cranial
nerve palsies have been reported in up to 27% of patients
(1,10). Also, restenosis occurs in 5% to 19% of patients, and
scarring from the initial operation can make repeat CE
difficult (9,15). Independent predictors of adverse outcome
include contralateral occlusion, previous ipsilateral CE and
combined coronary and carotid artery disease (CAD) (2,5–
14). Further, CE is limited to the cervical portion of the
carotid artery.
Recent studies suggest that carotid artery stenting (CAS)
is feasible in the treatment of carotid artery stenosis (16–
21). This procedure may prove to be safer, less traumatic
and more cost-effective. Moreover, the risk/benefit ratio
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may be greatest in patients at the highest risk for CE
(5,6,12–14). Further, CAS is not limited to the cervical
portion of the carotid artery. Advanced age and long or
multiple stenoses have been suggested as risk factors for an
adverse outcome (17), but few data are available to fully
characterize patient and procedure variables predictive of
success or adverse events.
In this report, we examine the safety and feasibility of
elective CAS in 170 consecutive patients at high risk for CE
because of the presence of concomitant symptomatic CAD,
contralateral carotid artery occlusion, previous ipsilateral
CE, anatomy unfavorable for CE or severe comorbidity.
METHODS
Patient group. A total of 170 consecutive patients referred
for elective stenting of the extracranial carotid arteries at the
Washington Adventist Hospital between August 1995 and
June 1998 were studied. Symptomatic patients with $70%
stenosis and asymptomatic patients with $60% stenosis in
the common or internal carotid artery, or both, were entered
into a protocol approved by the Institutional Review Board.
Patients were required to be $18 years old, agree to regular
follow-up and sign a written, informed consent form.
Patients with intracerebral tumor, arteriovenous malforma-
tion, previous disabling stroke and dementia were excluded.
Carotid stent protocol. All patients with a history of
documented CAD, or its suggestive symptoms, had coro-
nary angiography before CAS, when feasible. All patients
received aspirin (325 mg/day) and ticlopidine (250 mg twice
a day) for at least three days (or for 7 to 10 days in patients
with a transient ischemic attack [TIA], when feasible)
before CAS. Patients with angiographic evidence of throm-
bus and those with a recent CVA were given warfarin in
addition to aspirin for three to four weeks before CAS.
Three days before CAS, warfarin was stopped and ticlopi-
dine was started. Patients with symptomatic CAD who
were scheduled for a combined or staged intervention had a
coronary intervention first. In patients who had coronary
artery bypass graft surgery (CABG) planned, CAS was
performed first and then CABG was performed four weeks
later.
Coronary artery stenting was performed using coaxial
catheterization techniques adopted from coronary and other
endovascular interventions. A 9F arterial sheath was in-
serted into the femoral artery, and an 8F sheath was inserted
into the femoral vein for the placement of a temporary
pacing catheter. Heparin was given intravenously, beginning
with a bolus of 5,000 IU, as necessary, to maintain an
activated clotting time .250 s. When CAS and coronary
intervention were combined, the activated clotting time was
maintained at $300 s. A 5F carotid diagnostic catheter
(Mani, Cordis, Johnson & Johnson, The Netherlands) was
used to engage the carotid artery over an 0.038-in.
(0.096-cm) Terumo Glide wire. Then the catheter was
advanced into a branch of the external carotid artery. This
served as an exchange catheter for placement of an 0.038-
in., Amplatz Extra Stiff guide wire. After removal of the
diagnostic catheter, a 9F modified multipurpose guide
catheter with a 0.096-in. (0.24-cm) internal diameter was
advanced over the extra stiff exchange wire to a position just
proximal to the carotid lesion. Initially, a 0.014-in. (0.035-
cm) steerable coronary guide wire was used to cross the
lesion and was then exchanged for a 0.014-in. extra-support
guide wire (Advanced Cardiovascular Systems, Inc.,
Guidant, Temecula, California). Predilation was performed
using a low profile 4.0-mm coronary balloon. Thereafter, in
162 patients, balloon-expandable, stainless-steel, medium
sized (10 to 15 mm in length) Palmaz biliary stents
(Johnson & Johnson Interventional Systems Co., Warren,
New Jersey) were used. In eight patients, self-expandable
stents (Integra, Scimed, Boston Scientific, Watertown,
Massachusetts) were used. The biliary stents were mounted,
crimped and then delivered on a noncompliant peripheral
balloon of the appropriate size (balloon/artery ratio 1:1).
Stents were deployed with a single balloon inflation and
then dilated with the same balloon or with a larger balloon
using a higher pressure (10 to 12 atm). For a self-expanding
stent, balloon dilation was done using a slightly undersized
balloon with a low pressure (6 to 8 atm) inflation. In some
cases, multiple overlapping Palmaz stents were used. All
patients were given atropine sulfate (0.5 to 1.0 mg) before
balloon inflation. In patients with hypotension, metarami-
nol bitartrate (100 to 200 mg) was also given. Neurologic
status was continuously monitored both during and after
CAS by simple contralateral hand-gripping maneuvers. The
introducer sheaths were removed after the procedure when
the activated clotting time was #180 s and no further
anticoagulation was given. Patients were usually discharged
the day after the procedure. All patients were treated with
aspirin, 325 mg/day, indefinitely and ticlopidine, 250 mg
twice daily, for at least three weeks.
Clinical protocol. A complete neurologic examination,
including the National Institutes of Health (NIH) stroke
scale or a modified stroke scale, was performed by a
Abbreviations and Acronyms
ACAS 5 Asymptomatic Carotid Atherosclerosis
Study
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
CAS 5 carotid artery stenting
CE 5 carotid endarterectomy
CVA 5 cerebrovascular accident
MI 5 myocardial infarction
NASCET 5 North American Symptomatic Carotid
Endarterectomy Trial
NIH 5 National Institutes of Health
TIA 5 transient ischemic attack
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neurologist before CAS. Computed tomography of the
head and complete diagnostic cerebral angiography, includ-
ing assessment of the intracranial collateral circulation were
performed in all patients. The neurologic examination was
repeated at 24 h, 30 days, six months and one year after
CAS. Any change in neurologic status after CAS required
repeat computed tomography of the head. A carotid artery
ultrasound was performed at 30 days, six months and one
year after CAS. Follow-up angiography was recommended
for all patients at six months. Quantitative angiography was
performed before, immediately after and six months after
the procedure. Quantitative analysis was performed by an
independent observer who did not know the patient out-
come, using the ARTREK System (Imagecom, Mountain
View, California). The percent diameter stenosis was ob-
tained using the NASCET criteria, with the distal, nonta-
pering portion of the internal carotid artery serving as the
reference segment. The primary clinical end points assessed
included death, any major or minor stroke and myocardial
infarction (MI) within the first 30 days. Procedural success
was defined as a reduction in the stenosis to #30% and
absence of major stroke, MI or death.
Data collection and statistical methods. Clinical, angio-
graphic and procedural data were prospectively recorded on
a standardized form. The clinical and demographic variables
collected included age, gender, symptoms, severity of CAD,
presence or absence of diabetes mellitus, hypertension,
hyperlipidemia, history of smoking, bilateral carotid artery
stenosis or occlusion and whether the patient was random-
izable into NASCET or ACAS. For calculation of stroke
rates, the internal carotid plus ipsilateral common carotid
arteries were considered as a single vessel, whereas the left
internal carotid plus contralateral right internal carotid
arteries were considered as two vessels. All data are ex-
pressed as the mean value 6 SD; categoric variables are
expressed as percentages. Cumulative frequency distribu-
tions were constructed for minimal lumen diameter and
percent stenosis. Survival curves were drawn on an actuarial
basis using the Kaplan-Meier technique. Statistical analysis
was performed by using the chi-square test for discrete
variables. A p value ,0.05 was considered significant.
Definitions. MYOCARDIAL INFARCTION: Development of
new Q waves on the electrocardiogram (ECG) and/or a
creatine kinase elevation to at least twice the normal level,
accompanied by above-normal elevation of the MB band.
CATEGORY 1 MINOR STROKE: A new neurologic deficit that
changed the NIH stroke scale by 1 point and persisted for
.24 h, but completely resolved or returned to baseline
within seven days.
CATEGORY 2 MINOR STROKE: A new neurologic deficit that
either resolved completely or returned to baseline within 30
days or that changed the NIH stroke scale by 2 or 3 points.
By definition, both categories of minor stroke are nondis-
abling neurologic events.
MAJOR STROKE: A new neurologic deficit that persisted
after 30 days and that changed the NIH stroke scale by $4
points.
RESULTS
Patient characteristics. The demographic and clinical
characteristics of the 170 patients are shown in Table 1.
The majority of patients in this study were men, and 25%
were .80 years old. Almost one-half of them had
Canadian Cardiovascular Society class III or IV angina.
A history of CVA or TIA was present in .60% of
patients. One hundred twenty-nine patients (76%) would
have been excluded from NASCET and ACAS (Table
2), and 54 (31%) were referred for CAS by vascular
surgeons.
Ninety-two percent (156 of 170) of the patients had
CAD, as demonstrated by angiography. With respect to
carotid anatomy, 84% of the lesions were eccentric, 25% had
calcium present on fluoroscopy, 56% were of moderate to
severe tortuosity and 24% were surgically inaccessible
among symptomatic patients because of their location above
the “Blesdale line.” Among 104 symptomatic patients, 79
met NASCET exclusion criteria, as shown in Table 2.
Thirty-two of 51 patients with a recent CVA were antico-
agulated with warfarin before CAS because angiography
suggested the presence of thrombus. Three patients with a
critical lesion and suggestion of thrombus on initial angiog-
raphy did not require CAS, because of a decrease in the
Table 1. Baseline Clinical and Demographic Characteristics
(n 5 170)
Male 100 (59%)
Age (years)
Mean 6 SD 73 6 8
Range 50–89
Angina (NYHA functional class III or IV) 74 (44%)
Myocardial infarction (recent) 10 (6%)
LVEF #30% 44 (26%)
Symptomatic
CVA 51 (30%)
TIA 53 (31%)
Asymptomatic 66 (39%)
Previous ipsilateral CE 16 (9%)
Contralateral carotid artery occlusion 14 (8%)
Radical neck with radiation angitis 4 (2%)
Cervical spine fixation 1 (0.6%)
Diabetes mellitus 61 (36%)
Hypertension 159 (94%)
Chronic obstructive pulmonary disease 35 (21%)
Chronic renal insufficiency 33 (19%)
Current smokers 50 (29%)
Hyperlipidemia 117 (69%)
Data, except for age, are presented as the number (%) of patients.
CE 5 carotid endarterectomy; CVA 5 cerebrovascular accident; LVEF 5 left
ventricular ejection fraction; NYHA 5 New York Heart Association functional class;
TIA 5 transient ischemic attack.
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severity of stenosis to ,60% at follow-up angiography after
warfarin therapy.
Procedural results and complications. Procedural data are
shown in Table 3. A total of 192 carotid arteries in 170
patients were stented in a total of 183 procedures. A total of
265 stents (P104, n 5 130; P154, n 5 123; P204, n 5 4;
self-expanding, n 5 8) were deployed. The procedural
success rate was 99%. Most patients (64%) experienced
significant bradycardia with balloon inflation, and hypoten-
sion requiring metaraminol occurred in 17%. Two patients
who had contralateral carotid artery occlusion had transient
loss of consciousness with balloon inflation. Thirteen pa-
tients had bilateral carotid artery stents placed at least four
weeks apart. The mean stenosis before the procedure was
78 6 10% and 2 6 3% after stenting. A typical example of
angiographic results is shown in Figure 1. The reference
diameter of the stented arteries was 5.66 6 0.77 mm (95%
confidence interval [CI] 4.12 to 7.2), and the balloon/artery
ratio was 1:1. The cumulative frequency distribution of the
minimal lumen diameter before (95% CI 0.44 to 1.4) and
after CAS (95% CI 3.73 to 7.2) and at six-month follow-up
(95% CI 3.34 to 6.34) in 108 patients is shown in Figure 2.
Seventy-three patients had a coronary intervention. Of
these, 10 had their coronary intervention at the same time as
CAS because of unstable coronary symptoms, and 63 were
staged (coronary intervention followed by CAS at $24 h).
Eight patients required hemodynamic support during the
coronary intervention because of poor left ventricular func-
tion or hemodynamic instability. In addition, eight patients
had a peripheral vascular intervention during the index
admission. Four patients had CABG a mean of four weeks
(range 3 to 5) after CAS.
No deaths or MIs occurred during the hospital period or
in the 30 days after CAS. There was one major stroke and
two category 2 minor strokes, as well as two category 1
minor strokes, as shown in Table 4. The overall 30-day
incidence of stroke and death was 2.9% (major stroke 0.5%;
minor stroke 2.4%; death 0.0%) per patient. Other compli-
cations included nonoliguric renal failure (n 5 5), ischemic
bowel (n 5 1) and a hematoma that required blood
transfusion (n 5 1). No episodes of cranial nerve palsy
occurred. Figure 3 shows that the mean NIH stroke scale at
baseline was 0.96 6 2.2 and 1.01 6 2.0 at 24 h. This was
not statistically significant (p 5 0.55). The NIH stroke scale
score at four to six weeks of follow-up was 0.93 6 1.82. The
mean length of hospital stay after CAS was 1.86 days.
Late follow-up. Kaplan-Meier curves for survival free of
death, MI, any stroke or any event are shown in Figure 4.
Three non–Q wave MIs occurred during the 19-month
follow-up. There were nine deaths during this time, none of
which were attributed to a neurologic cause. Three patients
had minor strokes, both category 2 (ipsilateral in two and
contralateral in one patient). No major strokes occurred
during the follow-up period. Two of the three patients with
minor strokes had a MI and one had documented left
ventricular thrombus. One hundred fifty-four patients were
eligible for six-month duplex ultrasound and angiographic
follow-up. Carotid artery duplex ultrasonography was done
in 152 patients, and 108 (70%) had angiographic follow-up
as well. Three patients had asymptomatic restenosis, and
one had a mild degree of stent deformity. All three patients
with restenosis (stenosis $60%) were successfully redilated.
DISCUSSION
This study demonstrates that CAS is both feasible and safe
in high-risk patients. In the 170 patients reported herein,
there were no procedural deaths or MIs and only one major
stroke. These results were achieved despite the fact that 76%
of the patients in this series would have been excluded from
NASCET and ACAS (2,4). Also, in this series, 73 of the
170 patients underwent both CAS and a coronary interven-
tion as a combined or staged procedure. These data suggest
that CAS may be an appropriate substitute for CE, at least
in patients at high risk for the latter procedure.
The resolution of obstruction to ,60% with anticoagu-
lation in almost 10% of patients with a recent stroke and
carotid artery thrombus on the arteriogram suggests that it
Table 2. Reason for North American Symptomatic Carotid
Endarterectomy Trial (NASCET) Exclusion in 79 Patients
Unstable angina 29 (37%)
Myocardial infarction (recent) 10 (12.6%)
Age $80 years 42 (53%)
Atrial fibrillation 35 (44%)
Severe comorbid conditions* 22 (28%)
Previous ipsilateral CE 15 (19%)
Surgically inaccessible lesions
Located above the mandible 19 (24%)
Located at the origin of the common
carotid artery
2 (2.5%)
*Severe comorbid conditions include severe heart, renal, lung failure or cancer likely
to cause death within five years. Data are presented as the number (%) of patients.
CE 5 carotid endarterectomy.
Table 3. Procedural Details
Total patients 170
Total procedures 183
Carotid arteries stented 192
ICA 168 (88%)
CCA only 9 (4%)
ICA 1 CCA 15 (8%)
Total stents deployed 265
Overlapping stents 52 (27%)
Bilateral carotid artery stents 13 (7.6%)
Coronary interventions 73 (43%)
Combined 10 (14%)
Staged 63 (86%)
CABG (staged) 4 (2%)
Data are presented as the number (%) of patients.
CABG 5 coronary artery bypass graft surgery; CCA 5 common carotid artery;
ICA 5 internal carotid artery.
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may be appropriate to delay CAS in such patients until they
complete a course of anticoagulation.
Comparison with previous studies. The NASCET and
ACAS studies have demonstrated that when CE is per-
formed by a highly skilled surgeon, operation is superior to
medical therapy in preventing CVA, both in symptomatic
and asymptomatic patients with high-grade carotid artery
stenosis (2,4). In NASCET, the risk of stroke or death was
5.8%, and in ACAS, it was 2.8% (2,4). Although 76% of the
patients would have been excluded from ACAS and
NASCET, our complication rate was comparable. By lim-
iting exclusion criteria to those that would make CAS
inappropriate, we were able to include a group that is
representative of the general population with cerebrovascu-
lar disease. This included 43% with symptomatic CAD who
underwent CAS and a coronary intervention as a combined
or staged procedure without major complications. Data
suggest that combined or staged CE and CABG is associ-
ated with stroke rates of 4.5% to 7.1% and mortality rates of
;5.5% (5,6,12–14).
Other investigators (17–21) have reported CAS in a
series of patients similar to ours. Of the 107 patients
reported (20), 77% would have been excluded from
NASCET or ACAS because of high risk. Four of the
patients experienced restenosis, consistent with our finding
of a low restenosis rate. Mathur et al. (17) studied the use of
Figure 1. An 82-year-old woman with a previous anterior MI (LVEF 25%) presented with unstable angina due to a critical left circumflex
coronary artery stenosis. After a successful coronary intervention, carotid angiography showed critical, tandem (arrows) right carotid lesions
(A) with an occluded contralateral internal carotid artery. Two (15-mm) Johnson & Johnson biliary stents were placed, with the proximal
stent covering the distal common carotid artery (B), with excellent angiographic results. Intracerebral angiography showed excellent
collateral filling (C) from the right carotid to the left anterior cerebral and middle cerebral arteries. (D) Follow-up duplex ultrasound at
six months showed a widely patent stent. RT ICA 5 right internal carotid artery.
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CAS in 231 patients with risk similar to that of our patients.
They experienced a major CVA rate of 0.7% and a minor
CVA rate of 6.2%. The authors identified advanced age and
long or multiple lesions as being independently predictive of
procedural CVA. These risk factors are different from those
reported for procedural complications of CE, specifically
contralateral carotid artery occlusion, previous CE and
combined carotid artery disease and CAD (8,12,14). De-
spite the fact that 25% of the patients in our study were .80
years, none had a procedural MI or major CVA, and there
was no difference among the ,70-year-old, 70- to 80-year-
old and .80-year-old age groups with respect to major or
minor CVA (Table 4). In all reported series, minor CVA
was the most common complication. In NASCET, for a
stroke to be “minor,” functional recovery needed to occur
within 90 days, whereas in our study and others (17,20,21),
functional recovery had to occur within seven days for
category 1 minor CVA or within 30 days for category 2.
These events would not have been recorded as strokes in
NASCET (2), where a detailed neurologic examination was
delayed for 30 days.
Interestingly, two patients had a lower 24-h stroke scale
after the procedure as compared with baseline. This finding
is similar that of Yadav et al. (20) and supports the notion
of a “hibernating” state of the brain, analogous to hibernat-
ing myocardium (22).
Procedural considerations and late outcome. The impor-
tance of pretreatment with aspirin and ticlopidine, as well as
its duration, in preventing complications is not clear, and a
randomized trial is needed to rigorously examine this issue.
However, given the demonstrated importance of these
agents in coronary stenting, such a trial seems unlikely to be
undertaken. In cases where there was a suggestion of
thrombus, patients were also treated with warfarin for three
to four weeks before CAS. Although this seems reasonable
from first principles, the importance of such treatment in
this setting has not been rigorously demonstrated. A tem-
porary pacemaker was placed in all patients in this study,
although it was rarely needed, and we no longer routinely
place a temporary pacemaker.
Overlapping stents (i.e., covering the body of the lesion)
Figure 2. Cumulative frequency distribution for minimal lumen
diameter before, immediately after and six months after the
procedure.
Figure 3. National Institutes of Health (NIH) stroke scale at
baseline, 24 h after carotid artery stenting and at follow-up.
Figure 4. Kaplan-Meier actuarial curves demonstrating survival
free from 1) myocardial infarction; 2) any stroke; 3) death; and 4)
all events, with event-free survival rates of 98.1%, 95.1%, 93.6%
and 88.2%, respectively, at a mean follow-up of 19 6 11 months.
At 12 months of follow-up, the rates were 98.3%, 95.1%, 95.1%
and 89.6%, respectively.
Table 4. Adverse Events by Age Group
Age
(years) n
Major
CVA
Minor
CVA*
All
Events†
,70 52 0 1 1
70–79 76 1 2 3
.80 42 0 1 1
*There were two category 2 minor strokes as well as two category 1 minor strokes.
†This includes all minor strokes (category 1 or 2) and major strokes combined (p 5
0.77).
CVA 5 cerebrovascular accident.
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were used to increase the radial strength and metallic
coverage of the Palmaz stents. Although we had only one
case of stent deformation, Mathur et al. (23) have reported
a 15% stent deformation rate. Current self-expanding
stents, which we now use exclusively, have sufficient radial
strength to make overlapping stents unnecessary. In fact,
deformation is virtually absent with self-expanding stents.
There were no late major CVAs or neurologic deaths
after hospital discharge. At a mean follow-up 19 6 11
months, there were only three patients (2%) with restenosis,
all of whom were successfully redilated. These results are
comparable to those reported by other investigators (17–20).
Clinical implications and future studies. In the low-risk
patients randomized into NASCET and ACAS, relief of
obstruction has been shown to lower the risk of CVA.
Whether relief of the obstruction in other patient groups
with different baseline characteristics would have the same
treatment advantage is not known with certainty, nor is the
relative effectiveness of CAS and CE in preventing CVAs
and death in these high-risk patients. During the 19-month
follow-up of patients in this study, there were very few
neurologic events, suggesting that the effectiveness of ob-
struction relief may well be reflected in long-term clinical
benefit. For this reason, randomized, controlled trials of CE
versus CAS are now the next step in evaluating CAS. Until
randomized trials are available, caution should be exercised
in discarding CE in patient groups in which it has been
proven effective. One randomized trial—the Carotid And
Vertebral Artery Transluminal Angioplasty Study
(CAVATAS), which examined the role of angioplasty
versus CE—has been completed (24). This trial, although
underpowered, suggested that balloon angioplasty without
routine stenting has a similar safety profile to elective CE.
These data suggest that routine stent implantation will
further improve the percutaneous management of carotid
artery disease. A second trial that compares CE and CAS—
the Carotid Revascularization Endarterectomy versus Stent
Trial (CREST), sponsored by the NIH—is planned (25).
The final results of CREST will not be available for at
least five to six years. In the interim, there are sufficient
published reports to support the use of CAS by experienced
operators in patients known to be at high risk for CE
(16–21). Such procedures require an experienced team of
neurologists and interventionalists. Patients at high risk for
CE include patients with carotid artery lesions above the C2
or C3 cervical vertebrae or at the ostium of the common
carotid artery and patients with cervical spine disease or
fixation, previous radical neck dissection, fibromuscular
dysplasia, previous cervical radiation, previous CE and the
presence of important comorbid conditions, including un-
stable angina, recent MI and severe congestive heart failure.
Whether the safety of CAS can be improved by the use of
glycoprotein IIb/IIIa inhibitors or distal neuroprotection
devices should be studied. In addition, there will be a
continuing evolution of new stents and postdilation strate-
gies that will require evaluation.
Study limitations. The primary limitation of this study is
that it is not a randomized trial. Also, CAS was performed
by one highly experienced operator in a single center.
Whether similar results will be obtained by less experienced
operators is not known. This study represents early clinical
experience with equipment designed for coronary and pe-
ripheral vascular interventions. Devices designed specifically
for carotid artery intervention may improve outcome.
Conclusions. This study demonstrates that CAS is feasible
and safe, even in patients who would have been excluded
from the NASCET and ACAS trials. Furthermore, pa-
tients known to be at high risk for CE (i.e., those with
contralateral carotid artery occlusion, previous CE, previous
radiation angitis and those undergoing a combined or staged
coronary intervention with CAS) had a complication rate
comparable to that of patients in the ACAS and NASCET
trials. Multicenter, randomized trials are under way and will
define the ultimate role of CAS.
Acknowledgments
The authors thank Bruce Rubin, MD, Susan Hoff, RN, and
Stephanie Cornell, RN, for their help in completing this
study. We also thank Gloria Valos for the quantitative
angiographic analysis, as well as Tamara Bulhack for her
assistance in the preparation of this manuscript.
Reprint requests and correspondence: Dr. Fayaz Shawl, Direc-
tor, Department of Interventional Cardiology, Washington Ad-
ventist Hospital, 7600 Carroll Avenue, Takoma Park, Maryland
20912. E-mail: fshawl@adventisthealthcare.com.
REFERENCES
1. Heart and Stroke Facts: 1996 Statistical Supplement. American Heart
Association, Dallas, Texas, 1996.
2. North American Symptomatic Carotid Endarterectomy Trial Collab-
orators. Beneficial effect of carotid endarterectomy in symptomatic
patients with high-grade carotid stenosis. N Engl J Med 1991;325:
445–53.
3. European Carotid Surgery Trialist’s Collaborative Group. Interim
results for symptomatic patients with severe (70–99%) or with mild
(0–29%) carotid stenosis. Lancet 1991;337:1235–43.
4. Executive Committee for the Asymptomatic Carotid Atherosclerosis
Study. Endarterectomy for asymptomatic carotid artery stenosis.
JAMA 1995;273:1421–8.
5. Graor RA, Hetzler NR. Management of coexistent carotid artery and
coronary artery disease. Curr Concepts Cerebrovasc Dis Stroke 1988;
23:19–23.
6. Newman DC, Hicks RG. Combined carotid and coronary artery
surgery: a review of the literature. Ann Thorac Surg 1988;45:574 –
81.
7. Sundt TM, Jr, Meyer FB, Piepgras DG, Fodee NC, Ebersold NJ,
Marsh WR. Risk factors and operative results. In: Meyer FB, editor.
Sundt’s Occlusive Cerebrovascular Disease, 2nd ed. Philadelphia:
W.B. Saunders, 1994;241–247.
8. Link MJ, Meyer FB, Cherry KJ, Orszulak TA, Fode NC. Combined
carotid and coronary revascularization. In: Meyer FB, editor. Sundt’s
Occlusive Cerebrovascular Disease, 2nd ed. Philadelphia: W.B. Saun-
ders, 1994:323–31.
1727JACC Vol. 35, No. 7, 2000 Shawl et al.
June 2000:1721–8 Safety and Efficacy of Carotid Artery Stenting
9. Zierler RE, Brandyk DF, Thiele BL, Strandness ED. Carotid artery
stenosis following endarterectomy. Arch Surg 1982;117:1408–15.
10. Lusby RJ, Wylie EJ. Complications of carotid endarterectomy. Surg
Clin North Am 1983;63:1293–301.
11. Winslow CM, Solomon DH, Chassin MR, Kosecoff J, Merrick NJ,
Brook RH. The appropriateness of carotid endarterectomy. N Engl
J Med 1988;318:721–7.
12. Rothwell PM, Slatterg J, Waslow CP. A systematic review of the risks
of stroke or death due to endarterectomy for symptomatic carotid
stenosis. Stroke 1996;27:260–5.
13. McCrory DC, Goldstein LB, Samsa GP, et al. Predicting complica-
tions of carotid endarterectomy. Stroke 1993;24:1285–91.
14. Gaseeki AP, Eliaszio M, Ferguson GG, Hachinski V, Barrnett HJ. Long
term prognosis and effect of endarterectomy in patients with symptomatic
severe carotid stenosis and contralateral stenosis or occlusion: results from
North American Symptomatic Carotid Endarterectomy Trial
(NASCET) group. J Neurosurg 1995;83:778–82.
15. Das MB, Hertzer NR, Ratcliff J, O’Hara PJ, Beven EG. Recurrent
carotid stenosis: a five year series of 65 operations. Ann Surg
1985;202:28–35.
16. Shawl FA, Efstratiou A, Hoff S, Dougherty K. Combined percutane-
ous carotid stenting and coronary angioplasty during acute ischemic
neurologic and coronary syndromes. Am J Cardiol 1996;77:1109–12.
17. Mathur A, Roubin GS, Iyer SS, et al. Predictors of stroke complicat-
ing carotid artery stenting. Circulation 1988;97:1239–45.
18. Wholey MH, Wholey M, Bergeron P, Diethrich EB, et al. Current
global status of carotid artery stent placement. Cathet Cardiovasc
Diagn 1998;44:1–6.
19. Dietrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery:
initial experience in 110 patients. J Endovasc Surg 1996;3:42–6.
20. Yadav JS, Roubin GS, Iyer SS, et al. Elective stenting of the
extracranial carotid arteries. Circulation 1997;95:376–81.
21. Roubin GS, Yadav S, Iyer SS, Vitek J. Carotid stent-supported
angioplasty: a neurovascular intervention to prevent stroke. Am J
Cardiol 1996:78 Suppl 3A:8–12.
22. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:
211–4.
23. Mathur A, Dorros G, Iyer SS, Vitek JJ, Yadav SS, Roubin G. Palmaz
stent compression following carotid artery stenting. Cathet Cardiovasc
Diagn 1997;41:137–40.
24. Major ongoing stroke trials: Carotid and Vertebral Artery Translumi-
nal Angioplasty Study (CAVATAS). Lancet 2000. In press.
25. Hobson RW, Brott R, Ferguson G, et al. CREST: Carotid Revascu-
larization Endarterectomy versus Stent Trial. Cardiovasc Surg 1997;
5:457–8.
1728 Shawl et al. JACC Vol. 35, No. 7, 2000
Safety and Efficacy of Carotid Artery Stenting June 2000:1721–8
